CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kempf, B. E.
Right arrow Articles by Vogt, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kempf, B. E.
Right arrow Articles by Vogt, P. K.
Cell Growth & Differentiation Vol. 10, 813-818, December 1999
© 1999 American Association for Cancer Research

A Genetic Analysis of PAX3-FKHR, the Oncogene of Alveolar Rhabdomyosarcoma1

Barbara E. Kempf and Peter K. Vogt2

The Scripps Research Institute, Division of Molecular and Experimental Medicine, La Jolla, California 92037

The PAX3-FKHR fusion protein of human alveolar rhabdomyosarcoma consists of the DNA-binding domains of PAX3 and the transcriptional activation domain of FKHR. It induces oncogenic transformation in cultures of chicken embryo fibroblasts (CEFs). PAX3-FKHR-transformed CEFs have been kept in continuous culture for more than 1 year; when quiescent, portions of the cultures differentiate into several distinct cell types. Deletion analysis suggests that both DNA binding and transcriptional activation are required for the induction of the PAX3-FKHR-transformed cellular phenotype. Mutant PAX3-FKHR proteins with reduced DNA binding or transactivation induce altered cellular morphologies and growth behavior distinct from that of CEFs expressing wild-type PAX3-FKHR. Mutant proteins that completely lack DNA binding or transactivation potential fail to transform.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Aoki, H. Jiang, and P. K. Vogt
Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins
PNAS, September 14, 2004; 101(37): 13613 - 13617.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. W. So and M. L. Cleary
Common mechanism for oncogenic activation of MLL by forkhead family proteins
Blood, January 15, 2003; 101(2): 633 - 639.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Zhang and C. Wang
PAX3-FKHR Transformation Increases 26 S Proteasome-dependent Degradation of p27Kip1, a Potential Role for Elevated Skp2 Expression
J. Biol. Chem., January 3, 2003; 278(1): 27 - 36.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. W. So and M. L. Cleary
MLL-AFX Requires the Transcriptional Effector Domains of AFX To Transform Myeloid Progenitors and Transdominantly Interfere with Forkhead Protein Function
Mol. Cell. Biol., September 15, 2002; 22(18): 6542 - 6552.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1999 by the American Association of Cancer Research.